Women’s Health Vaccine
The purpose of the study is to determine the safety, efficacy and immunogenicity of a 3 dose or 2 dose regimen of an investigation vaccine, versus placebo, in healthy adolescent and adult women to reduce the incidence of primary Cytomegalovirus (CMV) infection. CMV is a common virus that can infect almost anyone. Once infected, your body retains the virus for life. Most people don’t know they have CMV because it rarely causes problems in healthy people. If you are pregnant or have a weakened immune system, CMV is a cause for concern. A woman who develops active CMV infection during pregnancy can pass the virus to her baby, who might then experience signs and symptoms. CMV spreads from person to person through body fluids, such as blood, saliva, urine, semen and breast milk. The study investigational vaccine will be administered over a 6 month period; however, the study duration and number of clinic visits is open ended. Qualified participants will receive study-related care and medication at no cost, and may be compensated for study-related time and travel.
Millions of people lack the treatment they need to manage their conditions. As one of the largest and most recognized clinical study organisations in the world, Synexus provides a friendly relaxed environment where you have the opportunity to help others and maybe also yourself.
Who is Synexus?
Synexus is a company dedicated to conducting clinical studies, and has been investigating the effectiveness of new study drugs and treatments for more than 20 years. We provide a friendly, relaxed environment in our own clinics where you have the chance to help shape the future of health for yourself and for others.
We are sure you probably have more questions about the study, and we would be happy to take the time to give you more details.
All Synexus studies are approved by an independent ethics committee.